Paper Details

  1. Home
  2. Paper Details

Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

Author: BallardClive, BroadstockMartin, CorbettAnne

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Parkinson's disease, affecting 10 million worldwide, can lead to psychosis in half of patients. While most antipsychotics are ineffective or worsen motor symptoms, clozapine has shown efficacy, but side effects limit its use. Pimavanserin, a novel drug targeting serotonin, has proven effective in clinical trials for Parkinson's disease with psychosis.
Paper Details　
Original Abstract of the Article :
Parkinson's disease (PD) affects 10 million people worldwide. Half will develop psychosis, the majority experiencing hallucinations rather than delusions. Emergence of psychosis increases the likelihood of institutionalization and mortality. Where pharmacological treatment is warranted, options are ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1586/17512433.2014.966814

データ提供：米国国立医学図書館（NLM）

Novel Pharmaceuticals for Psychosis in Parkinson's Disease

Parkinson's disease (PD), a neurological disorder affecting millions worldwide, can present with a debilitating complication: psychosis. This research examines the current landscape of treatments for psychosis in PD and highlights promising advancements in pharmacological therapies. The authors review the limitations of existing antipsychotics and discuss the emergence of novel drugs like pimavanserin, which has shown efficacy in clinical trials. This study provides valuable insights into the evolving field of PD treatment, offering hope for individuals experiencing psychosis alongside their PD.

Pimavanserin Offers Hope for Psychosis in Parkinson's Disease

Pimavanserin stands out as a promising new treatment option for psychosis in PD. The drug has demonstrated efficacy in clinical trials, offering relief for patients who have struggled with existing treatments. This breakthrough represents a significant advancement in the management of PD-related psychosis.

Navigating the Complexities of Parkinson's Disease Treatment

This research underscores the complexity of PD treatment. The emergence of psychosis adds another layer of challenge, requiring careful consideration of therapeutic options. The development of pimavanserin represents a positive step towards providing more effective and targeted treatment for individuals with PD and psychosis. It is a testament to the ongoing efforts of researchers to improve the lives of those affected by this debilitating disease.

Dr.Camel's Conclusion

Imagine a camel navigating a desert, facing both the scorching heat and the relentless wind. Parkinson's disease can be like a desert, presenting its own unique challenges, and psychosis can be like a fierce wind, further complicating the journey. This research offers a beacon of hope, like a shimmering oasis in the desert, with pimavanserin presenting a new path towards alleviating psychosis in individuals with PD.

Date :
  1. Date Completed 2015-06-15
  2. Date Revised 2014-10-16
Further Info :

Pubmed ID

25301532

DOI: Digital Object Identifier

10.1586/17512433.2014.966814

Related Literature

Article Analysis
・Side Effects of pimavanserin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.